Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nike Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.67 (market cap $8.04B), while Nike Inc trades at $43.53 (market cap $63.47B). The key difference: Nike Inc is far larger — about 7.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Nike Inc pays a 3.83% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NKE | |
|---|---|---|
Market Cap | $8.04B | $63.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $79.24 |
52-Week Low | $241.71 | $40.75 |
Enterprise Value | $7.85B | $65.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Nike (NKE) trades at $43.76, down 1.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $46.31B for 2025 with a net income margin of 6.7%, though earnings have beaten expectations in recent quarters. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting potential upside from current levels.
Nike's outlook is supported by strong brand equity and consistent earnings beats, but faces headwinds from softer demand in China and margin pressure. The stock presents a value opportunity with a P/E of 20.41 below historical averages, though execution risks in the turnaround strategy remain key for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
